The use of decentralized clinical trials (DCTs) exploded during the pandemic, but quantifying their financial benefits has been elusive.
Medable (Palo Alto, California), the maker of a cloud-based DCT platform, has announced that DCTs can accelerate clinical trial timelines and lead to significant cost savings.
Medable and its research partner, the Tufts Center for the Study of Drug Development (CSDD), found that for Phase 2 studies, a standard DCT deployment yielded a one-to-three month time savings over a traditional Phase 2 study. In addition, a DCT yielded a financial benefit that is up to five times more than the upfront investment.
Time savings for Phase 3 studies were similar, while the net financial benefit was up to 14 times more than the upfront investment.
To learn more about the recent research, we spoke with Dr. Pamela Tenaerts, chief s…